The past few weeks have seen a spate of pharma manufacturing cuts, with Actavis, Merck and Pfizer all whacking jobs. And Pfizer has continued its busy end to 2013 by revealing it is to close a packaging plant in Ireland, laying off 150 workers in the process.
France's Pixium Vision reeled in $20.3 million in new financing to help further development of the company's retinal implant system designed to help people with certain degenerative eye conditions see better.
France's AB Science watched its shares tank as much as 31% on Friday after a European Medicines Agency panel rejected its gastrointestinal cancer treatment, casting serious doubts on the drug's potential approval.
Respiratory device company ResMed secured preliminary injunctions in Germany against two rivals based in mainland China and Taiwan in what has become a global patent fight.
Boston Scientific's Vercise deep brain stimulation system isn't yet approved in the U.S., but it continues to rack up regulatory blessings overseas. In the latest advance, the product now has a CE mark to treat a neurological movement disorder known as dystonia.
A German appeals court lifted an injunction preventing the sale of Medtronic's transcatheter aortic heart valve in the country, a major defeat for archrival Edwards Lifesciences and the latest development in a nasty patent fight that long ago went international.
AstraZeneca has decided that the experience it has at its plant in Macclesfield, England, which has produced its prostate cancer drug Zoladex for 25 years, make it the best location for its new £120 million ($190 million) plant to manufacture the sterile drug.
Bacterin International is expanding into Europe and has allied with a distributor to help execute its plan. The Montana maker of bone graft materials and medical coatings said it would work with DMP Spine Biologics to distribute its products throughout the European Union.
Metal-on-metal hips have been in trouble around the world for years due to heightened safety concerns, and now the U.K. government will ban their use in National Health Service hospitals.
A pair of prominent pharma players are partnering up with a few marquee European VCs to back an up-and-coming immunotherapy biotech based in Vienna.